Quotes 5-day view Delayed Nasdaq
01/15/2021
01/19/2021
01/20/2021
01/21/2021
01/22/2021
Date
80.5(c)
80.7(c)
81.22(c)
76.66(c)
77.68(c)
Last
471 294
620 506
468 194
456 456
480 902
Volume
-0.07% +0.25% +0.64% -5.61% +1.33% Change
Sales 2020
0,74 M - -
Net income 2020
-390 M - -
Net cash position 2020
828 M - -
P/E ratio 2020
-10,9x
Yield 2020
-
Sales 2021
26,5 M - -
Net income 2021
-453 M - -
Net cash position 2021
575 M - -
P/E ratio 2021
-10,3x
Yield 2021
-
Capitalization
4 518 M 4 518 M -
EV / Sales 2020
4 973x
EV / Sales 2021
149x
Nbr of Employees
320
Free-Float
98,7%
Arena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II...
Notations Surperformance© of Arena Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
All news about ARENA PHARMACEUTICALS, INC.
News in other languages on ARENA PHARMACEUTICALS, INC.
- No features available -
Analyst Recommendations on ARENA PHARMACEUTICALS, INC.
Chart ARENA PHARMACEUTICALS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ARENA PHARMACEUTICALS, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
14
Average target price
94,79 $
Last Close Price
77,68 $
Spread / Highest target
49,3%
Spread / Average Target
22,0%
Spread / Lowest Target
-2,16%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
